Abstract: Combinations of the novel biological markers that can be used in the diagnosis of endometriosis are provided. The objective of the invention is to detect biological markers that are expressed differently in eMSCs isolated from endometrial biopsy samples in the diagnosis of endometriosis compared to healthy eMSCs. A tissue transglutaminase is configured as a biomarker for a diagnosis of an endometriosis in isolated endometrial mesenchymal stem cells derived from an endometrial biopsy and/or a menstrual blood from endometriosis patients.

Abstract: A chemotherapeutic drug composition, prepared by combination of Everolimus, one of the drugs used in the treatment of the metastatic renal cell carcinoma (RCC) comprising 2-3% of the malignant tumors, with the anti-apoptotic Bcl-2 inhibitor ABT-737 for the treatment of RCC tumors that developed drug resistance. The effect of Everolimus and ABT-737 drug composition on cell survival and cell death in Everolimus-resistant RCC cell lines overexpressing Bcl-2 protein was shown by in vitro and in vivo experiments and the mechanism of the effect of the drug composition on RCC has been examined from a molecular point of view. Navitoclax (ABT-263), an orally available analog of ABT-737, and other Bcl-2 inhibitors alone or in combination with Everolimus, which is administered once a day at a dose of 10 mg, for the use in the treatment of Everolimus-resistant RCC.

Abstract: A chemotherapeutic drug composition, prepared by combination of Everolimus, one of the drugs used in the treatment of the metastatic renal cell carcinoma (RCC) comprising 2-3% of the malignant tumors, with the anti-apoptotic Bcl-2 inhibitor ABT-737 for the treatment of RCC tumors that developed drug resistance. The effect of Everolimus and ABT-737 drug composition on cell survival and cell death in Everolimus-resistant RCC cell lines overexpressing Bcl-2 protein was shown by in vitro and in vivo experiments and the mechanism of the effect of the drug composition on RCC has been examined from a molecular point of view. Navitoclax (ABT-263), an orally available analog of ABT-737, and other Bcl-2 inhibitors alone or in combination with Everolimus, which is administered once a day at a dose of 10 mg, for the use in the treatment of Everolimus-resistant RCC.

Abstract: The present invention provides a method for identifying a drug-like compound, or lead compound for the development of a drug-like compound, which is capable of modulating cellular adhesion and/or cell survival comprising the step of testing said compound for an ability to modulate the binding of a complex of tissue transglutaminase and fibronectin to a heparan sulfate containing receptor. In particular, there is provided a method for identifying a compound for use in the curative and/or prophylactic treatment of a proliferative disorder or with efficacy in promoting wound healing and /or cell survival, and compounds identified by such methods.